VA Boston Healthcare System, National Center for PTSD
Boston, Massachusetts, 02130, United States
NCT Number: NCT00862498
This study will test the effectiveness of writing about a traumatic incident to treat post-traumatic stress disorder in people who have been in car accidents.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02130, United States
Post-traumatic stress disorder (PTSD) is a chronic and debilitating disorder caused by experiencing a stressful or traumatic event. Although there is evidence that treatments for PTSD are effective, many people do not seek treatment or seek treatment only after their PTSD has become severe. This study will test a low-cost, brief, and easily implemented treatment that may encourage people to seek treatment for PTSD. The treatment, called written disclosure (WD), involves writing about the traumatic event that caused a person's PTSD. In this study, people who have PTSD as the result of a motor vehicle accident will test two versions of WD, one administered in a clinic and the other administered over the phone.
Participation in this study will last 5 weeks, with follow-up assessments continuing until 6 months after treatment. After screening, participants will be assigned to one of three conditions: WD treatment delivered in the clinic, WD treatment delivered via phone, and waitlist. The WD treatment involves five weekly writing sessions. During the first session, trauma reactions and the rationale for WD will be explained to all participants, and then participants will write for 30 minutes about their motor vehicle accident. The next four sessions will involve only writing for 30 minutes. For those receiving treatment in the clinic, a therapist will communicate directions and explanations to participants, and participants will have their heart rate activity recorded continuously for 5 minutes prior to writing and during the 30 minutes of writing. For those receiving treatment over the phone, explanations of the study will be provided in writing, and a study staff member will call participants before and after each writing session to ensure that participants understand the directions and are not experiencing any unexpected negative reactions after writing. Participants in the waitlist condition will not receive treatment for the first 4 months. After that period, they will be offered the WD treatment.
Assessments of all participants will occur at baseline, after treatment, and 3 months after treatment. Participants assigned to receive WD treatment, either in a clinic or via phone, will also be assessed 6 months after treatment. Assessments administered at these points will involve semi-structured clinical interviews, self-report questionnaires, and measures of mood-related symptoms. Participants receiving treatment will also complete self-report measurements of emotional response after each writing session and the Daily Experiences Questionnaire every day during the 5 weeks of treatment. Participants on the waitlist will also undergo assessments of suicidal thoughts and PTSD symptoms every 2 weeks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
Other names: Written Emotional Disclosure, Narrative Writing, Narrative Exposure
Time frame: Measured at baseline, post-treatment, and at 3- and 6-month follow-ups
Time frame: Measured at baseline, post-treatment, and at 3- and 6-month follow-ups
Time frame: Measured at baseline, post-treatment, and at 3- and 6-month follow-ups
Time frame: Measured at baseline, post-treatment, and at 3- and 6-month follow-ups
Time frame: Measured at the end of the last treatment session
Time frame: Measured every day during the 5-week treatment period
Time frame: Measured at baseline, post-treatment, and at 3- and 6-month follow-ups
Time frame: Measured at baseline, post-treatment, and at 3- and 6-month follow-ups
Time frame: Measured after each writing session
Time frame: Measured after the last writing session
Time frame: Measured after the 3-month follow-up assessment
Time frame: Measured at baseline, post-treatment, and at 3- and 6-month follow-ups
Time frame: Measured at baseline, post-treatment, and at 3- and 6-month follow-ups
Boston University
Other
Examining Written Disclosure as an Intervention for Posttraumatic Stress Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05512143
Cardiovascular Diseases, Hypertension
Providence, Rhode Island, United States
View Trial DetailsNCT03194386
Mental Disorders, Post-traumatic Stress Disorder
Bordeaux, France
View Trial DetailsNCT03519789
Mental Disorders, Post-traumatic Stress Disorder
Lille, France
View Trial DetailsNCT00739765
Anxiety Disorders, Mental Disorders
New York, United States
View Trial Details